NCT00424866.

Trial name or title	NCT00424866 ("FGF‐1 for intramuscular injection for the treatment of peripheral arterial disease")
Methods	Randomised, phase 1, open label, dose response, pilot study
Participants	People with peripheral arterial disease and intermittent claudication (N = 24, plan)
Interventions	FGF‐1: low dose (3.0 μg/kg), medium dose (10 μg/kg), high dose (30 µg/kg) vs placebo
Outcomes	Safety and tolerability
Starting date	December 2014
Contact information	CardioVasc BioTherapeutics Inc.
Notes	The study is not yet open for participant recruitment Estimated study completion date: December 2014 Data from CardioVasc BioTherapeutics Inc. inquired